MedTrace Logo

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

NCT01741545 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2020-08-11

Study results available
· View outcomes & findings →

Summary

The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3

Conditions

  • Hepatitis C Virus

Interventions

BIOLOGICAL

Pegylated-Interferon-lambda

DRUG

Ribavirin

DRUG

Daclatasvir

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States
  • Australia
  • France
  • Italy
  • Netherlands
  • Romania
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741545 on ClinicalTrials.gov